

## DAFTAR PUSTAKA

- Aesha, Tanveer, S., dan Sreeja, 2014. Bisphosphonates-Osteonecrosis of Jaw. *Systematic Reviews in Pharmacy*, **5**: 1–3.
- Alegre, A., Gironella, M., Alicia, B., dan Giraldo, P., 2013. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. *European Journal of Haematology*, **92**: 181–188.
- Andayani TM, 2013. *Farmakoekonomi : Prinsip Dan Metodologi*. Yogyakarta: Bursa Ilmu.
- Ashcroft, J., Duran, I., Hoefeler, H., Lorusso, V., Lueftner, D., Campioni, M., dkk., 2018. Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study. *European Journal of Haematology*, **100**: 479–487.
- Aviles, A., Nambo, M.J., Neri, N., Castañeda, C., Cleto, S., dan Huerta-Guzmán, J., 2007. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. *Medical Oncology*, **24**: 227–230.
- Aviles, A., Neri, N., Huerta-Guzman, J., dan Nambo, M.J., 2013. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. *Current Oncology*, **20**: E14–E20 .
- Barlev, A., Xue, S., Ivanov, B., Setty, V., dan Chung, K., 2010. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. *Journal of Managed Care Pharmacy*, **16**: 693–702.
- Blommestein, H.M., Verelst, S.G.R., de Groot, S., Huijgens, P.C., Sonneveld, P., dan Uyl-de Groot, C.A., 2016. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. *European Journal of Haematology*, **96**: 198–208.
- Botteman, M.F., Meijboom, M., Foley, I., Stephens, J.M., Chen, Y.M., dan Kaura, S., 2011. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. *The European Journal of Health Economics*, **12**: 575–588.
- BPOM RI, 2010. *IONI*. <http://pionas.pom.go.id/ioni/bab-6-sistem-endokrin/66-gangguan-metabolisme-tulang/662-bifosfonat-dan-obat-lain/bisfosfonat>. (diakses 2/6/2018).

- Cancer.net, (2018), Multiple myeloma : Statistics. <https://www.cancer.net/cancer-types/multiple-myeloma/statistics>. (diakses 6/22/2020).
- Chadha, V., 2006. Sample size determination in health studies. *NTI Bulletin*, **42**: 55–65.
- Davis, S., Martyn-St James, M., Sanderson, J., Stevens, J., Goka, E., Rawdin, A., dkk., 2016. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. *Health Technology Assessment*, **20**: 1–406.
- De Cock, E., Hutton, J., Canney, P., Body, J., Barret-Lee, P., Neary, M., dkk., 2005. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. *Support Care Cancer*, **13**: 975–986.
- Delea, T., Rotter, J., Taylor, M., Chandiwana, D., Bains, M., El Ouagari, K., dkk., 2012. Cost-effectiveness of zoledronic acid vs clodronic acid for newly diagnosed multiple myeloma from the United Kingdom healthcare system perspective. *Current Oncology*, 392–402.
- Department of Economics and Public Health dan Assessment, 2012. *Choices in Methods for Economic Evaluation (A Methodological Guide)*. Haute Autorite De Sante, Oktober 2012.
- Despiéglé, N., Touboul, C., Flinois, A., Saba, G., Suzan, F., Gonzalez-McQuire, S., dkk., 2019. Health-Related Quality of Life of patients with multiple myeloma treated in routine clinical practice in France. *Clinical Lymphoma Myeloma and Leukemia*, **19**: e13–e28.
- Dewi, M., 2017. Sebaran Kanker di Indonesia, Riset Kesehatan Dasar 2007. *Indonesian Journal of Cancer*, **11**: 1–8.
- Dispenzieri, A., Lacy, M., dan Greipp, P., 2004. Multiple Myeloma, dalam: *Hematologic Malignancies : Multiple Myeloma and Related Plasma Disoorders*.
- Durán, I., Garzón, C., Sánchez, A., García-Carbonero, I., Pérez-Gracia, J.L., Seguí-Palmer, M.Á., dkk., 2014. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. *Clinical and Translational Oncology*, **16**: 322–329.
- Euroqol, 2017. 'EQ-5D', org, *EQ-5D*. URL: <https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/> (diakses tanggal 17/11/2017).
- Fardellone, P., Cortet, B., Legrand, E., Bresse, X., Locard, B., Vigneron, A., dkk., 2010. Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis. *Joint Bone Spine*, **77**: 53–57.
- Gabbert, T., Hoffmeister, B., dan Felsenberg, D., 2014. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an

- osteonecrosis of the jaw in 963 cancer patients. *Journal Cancer Research Clinical Oncology*, **141**: 749–758.
- Garcia-Sanz, R., Oriol, A., Moreno, M.J., de la Rubia, J., Payer, A.R., Hernandez, M.T., dkk., 2015. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. *Haematologica*, **100**: 1207–1213.
- Geng, C.-J., Liang, Q., Zhong, J.-H., Zhu, M., Meng, F.-Y., Wu, N., dkk., 2015. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. *BMJ open*, **5**: e007258.
- Globocan, 2018. 360 Indonesia Fact Sheets. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf> (diakses tanggal 30/4/2020)
- Haacker, M., Hallet, TB., Atun, R., 2019. On discount rates for economic evaluations in global health. *Health Policy and Planning*. **35** : 107 – 113.
- Hagiwara, M., Oglesby, A., Chung, K., Zilber, S., dan Delea, T.E., 2011. The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. *Community Oncology*, **8**: 508–515.
- Hillner, B., Weeks, J., Desc, C., dan Smith, T., 2000. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. *Journal of Clinical Oncology*, **18**: 72–79.
- Himelstein, A., Foster, J., Khatcheressia, J., Roberts, J., Seisler, D., Novotny, P., dkk., 2017. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A Randomized Clinical Trial. *JAMA*, **317**: 48–58.
- Holder, V., 2014. 'The cost-effectiveness of pomalidomide for treating patients with relapsed multiple myeloma refractory to both lenalidomide and bortezomib', Thesis. Erasmus University Rotterdam, Institute of Health Policy and Management, Rotterdam.
- Kemenkes RI, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan Republik Indonesia.
- Kemenkes RI, 2016. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02 / MENKES / 137 / 2016 tentang Perubahan atas Keputusan Menteri Kesehatan No. HK.02.02 / MENKES / 523 / 2015 Tentang Formularium Nasional.
- Kemenkes RI, 2017. *Buku Panduan Penilaian Teknologi Kesehatan (Efektivitas Klinis Dan Evaluasi Ekonomi)*. Pusat Pembiayaan dan Jaminan Kesehatan, Kementerian Kesehatan RI, Jakarta. Halaman : 107 - 146
- Khan, A.A., Morrison, A., Hanley, D.A., Felsenberg, D., McCauley, L.K.,

- O’Ryan, F., dkk., 2015. Diagnosis and management of osteonecrosis of the jaw: A Systematic review and international consensus: Osteonecrosis of the jaw: Report from the international ONJ task force. *Journal of Bone and Mineral Research*, **30**: 3–23.
- Kim, Y.-H., Park, H.-K., Choi, N.-R., Kim, S.-W., Kim, G.-C., Hwang, D.-S., dkk., 2017. Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw. *Journal of the Korean Association of Oral and Maxillofacial Surgeons*, **43**: 16.
- Kusmini, K., Satibi, S., dan Suryawati, S., 2016. Evaluasi pelaksanaan *e-purchasing* obat pada dinas kesehatan kabupaten/kota di Jawa Tengah tahun 2015. *Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **6**: 277.
- Li, S., Natwick, T., Liu, J., Morrison, VA., Vidito, S., Werther, W., dkk., 2019. Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States. *Journal of Geriatric Oncology*, **10**: 490 – 496.
- Lawrence, L., 2018. Multiple Myeloma Incidence Increasing Worldwide, Especially in the US. <https://www.cancernetwork.com/view/multiple-myeloma-incidence-increasing-worldwide-especially-us>. (diakses: 1/1/2019)
- Machado, M., Cruz, L., Tannus, G., dan Fonseca, M., 2009. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A Meta-analysis of Randomized Clinical Trials. *Clinical Therapeutics*, **31**: 962–979.
- Matza, L.S., Chung, K., Van Brunt, K., Brazier, J.E., Braun, A., Currie, B., dkk., 2014. Health state utilities for skeletal-related events secondary to bone metastases. *The European Journal of Health Economics*, **15**: 7–18.
- Menssen, H.D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., dkk., 2002. Effects of long-Term intravenous ibandronate therapy on skeletal-related events, *survival*, and bone resorption markers in patients with advanced multiple myeloma. *Journal of Clinical Oncology*, **20**: 2353–2359.
- Merola, D., Yong, C., Noga, S.J., dan Shermock, K.M., 2018. Costs associated with productivity loss among U.S. patients newly diagnosed with multiple myeloma receiving oral *versus* injectable chemotherapy. *Journal of Managed Care & Specialty Pharmacy*, **24**: 1019–1026.
- Mhaskar, R., Kumar, A., dan Djulbegovic, B., 2017. Bisphosphonates in multiple myeloma: an updated network meta-analysis (Review ). *Cochrane Library (Cochrane Database of Systematics Reviews)*, **12** : 1-87 .

- Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O., Miladinovic, B., dan Glasmacher, A., 2010. Bisphosphonates in multiple myeloma (*Review*). *The Cochrane Collaboration*, 3 : 1 -84.
- Mohebbifar, R., Pakpour, A.H., Nahvijou, A., dan Sadeghi, A., 2015. Relationship between spiritual health and quality of *life* in patients with cancer. *Asian Pacific Journal of Cancer Prevention*, **16**: 7321–7326.
- Morgan, G.J., Davies, F.E., Gregory, W.M., Cocks, K., Bell, S.E., Szubert, A.J., dkk., 2010. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet*, **376**: 1989–1999.
- Morris, S., Devlin, N.J., dan Parkin, D., 2007. *Economic Analysis in Health Care*. J. Wiley & Sons, Chichester ; Hoboken, NJ.
- Multiple Mieloma Indonesia, 2016a. 'Multiple myeloma Indonesia (Media Komunikasi Antar Anggota)'. *Multiple Mieloma Indonesia*, **1**: 2 - 4.
- Multiple Mieloma Indonesia, 2016b. Stadium MM – Multiple Myeloma Indonesia.
- NCCN, 2017a. Multiple myeloma (NCCN clinical practice guidelines in oncology).
- NCCN, 2017b. Multiple Myeloma (NCCN evidence blocks).
- NCCN, 2019. Multiple myeloma Version 1. 2020 (NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)).
- Ottesen, C., Schiodt, M., dan Gotfredsen, K., 2020. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review . *Heliyon*, **6**: e03795.
- Palmieri, C., Fullarton, J., dan Brown, J., 2013. Comparative efficacy of Bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: A Mixed-treatment meta-analysis. *American Association for Cancer Research*, **19**: OF1–OF10.
- Paterson, A., McCloskey, E., Redzepovic, J., Ott, I., dan Gust, R., 2008. Cost-effectiveness of oral Clodronate compared with oral Ibandronate, intravenous Zoledronate or intravenous Pamidronate in breast cancer patients. *The Journal of International Medical Research*, **28**: 400–413.
- Petrucci, M.T., Calabrese, E., Levi, A., Federico, V., Ceccolini, M., Rizzi, R., dkk., 2013. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. *Tumori*, **99**: 193–202.
- Pozzi, S. dan Raje, N., 2011. The Role of Bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. *The Oncologist*, **16**: 651–662.
- Purba, F.D., Hunfeld, J.A.M., Iskandarsyah, A., Fitriana, T.S., Sadarjoen, S.S., Ramos-Goñi, J.M., dkk., 2017. The Indonesian EQ-5D-5L value set.



*Pharmacoeconomics*, **35**: 1153–1165.

- Raje, N., Roodman, G.D., Willenbacher, W., Shimizu, K., Garcia-Sanz, R., Terpos, E., dkk., 2018. A *cost effectiveness analysis of denosumab for the prevention of skeletal related events in patients with multiple myeloma in the united states of America*. *Journal of Medical Economics*, **21**: 525-536.
- Schwartzova, V., Riznic, M., Borza, B., dan Kizek, P., 2018. Osteonecrosis of the Jaws, dalam: Khan, W.A. (Ed.), *Newest Updates in Rheumatology*. InTech.
- Setiawan, D., Endarti, D., dan Suwantika, AA., 2017. *Farmakoekonomi Modeling*. UMP Press, Purwokerto.
- Shah, D. dan Seiter, K., 2020. Multiple myeloma treatment and management.
- Sosialine, E., 2018. 'Lima tahun perjalanan E-katalog obat', dalam: *Lima Tahun Perjalanan E-Katalog Obat*. Dipresentasikan pada Pertemuan Ilmiah Tahunan Ikatan Apoteker Indonesia, Pertemuan Ilmiah Tahunan Ikatan Apoteker Indonesia, Pekanbaru.
- Suega, K. dan Sjah, Y., 2009. Terapi terkini multiple myeloma. *Jurnal penyakit dalam*, **10**: 226–239.
- Sutandyo, N., Firna, E., Agustina, J., Prayogo, N., dan Widjaja, L., 2015. Clinicopathology profile and bone involvement of multiple myeloma patients in Dharmas National Cancer Hospital, Indonesia. *Asian Pacific Journal of Cancer Prevention*, **16**: 6261–6265.
- Tadjoedin, H., Reksodiputro, A., Toruan, T., Abdulmutholib, Kosasih, A., Supandiman, I., dkk., 2011. Multiple myeloma in Indonesia. *Indonesian Journal of Cancer*, **5**: 76–81.
- Tan, D., Lee, J., Chen, W., Shimizu, K., Hou, J., Kenshi, S., dkk., 2018. Recent advances in the management of multiple myeloma: clinical impact based on resource stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. *Leukemia & Lymphoma*, **59** : 2305-2307 .
- Terpos, E., Viniou, N., De la Fuente, J., Voskaridou, E., Karkantaridis, C., Vaiopoulos, G., dkk., 2003. Pamidronate is superior to ibandronate in decreasing bone resorption interleukin-6 and b 2-microglobulin in multiple myeloma. *Eur J Haematol*, **70** : 34 -42
- Terpos, E., Jamotte, A., Christodouloupoulou, A., Campioni, M., Bhowmik, D., Kennedy, L., dkk., 2019. A *cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy*. *Journal of Medical Economics*, **22**: 766–776.
- Union for International Cancer Control, 2016. Bisphosphonate therapy (2016 *Review of cancer medicines on the WHO list of essential medicines*).

- Vahtsevanos, K., Kyrgidis, A., Verrou, A., Katodritou, E., Triaridis, S., Andreadis, C., dkk., 2009. Longitudinal cohort study of risk factors in cancer patients of Bisphosphonate-related osteonecrosis of the jaw. *Journal of Clinical Oncology*, **27**: 5356–5362.
- Watts, NB dan Diab, DL, 2010. Long Term Use of Bisphosphonates in Osteoporosis. *The Journal of Clinical Endocrinology & Metabolism*, 95 (4): 1555 - 1565
- Weide, R., Koppler, H., Antras, L., Michael, S., Chang, E., Green, J., dkk., 2010. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review. *Journal Cancer Research Therapy*, **6**: 31–35.
- WHO, 2018. Indonesia *Life Table* 2016. <https://apps.who.int/gho/data/view.main.60750?lang=en>. (diakses 5/1/2020)
- Winda, S., 2018. Formularium Nasional (FORNAS) dan e-catalogue obat Sebagai upaya pencegahan korupsi dalam tata kelola obat Jaminan Kesehatan Nasional (JKN) **4**: 30.
- World Health Organization, 2005. *Guidelines for Estimating the Economic Burden of Diarrhoeal Disease, with Focus on Assessing the Costs of Rotavirus Diarrhoea*. The Vaccine Assessment and Monitoring Team of the Department of Immunization, Vaccines and Biologicals. Geneva, Switzerland
- Wu, S., Dahut, W., dan Gulley, J., 2007. The use of bisphosphonates in cancer patients. *Acta Oncologica*, **46**: 581–591.